7 Immune thrombocytopenic purpura in pregnancy

MD, PhD G.C.M.L. Christiaens (Gynaecologist)
{"title":"7 Immune thrombocytopenic purpura in pregnancy","authors":"MD, PhD G.C.M.L. Christiaens (Gynaecologist)","doi":"10.1016/S0950-3536(98)80055-3","DOIUrl":null,"url":null,"abstract":"<div><p>Of all pregnant women 1.2% have platelet counts below 100×10<sup>9</sup>/l. Only a small proportion of these have immune thrombocytopenic purpura (ITP). ITP is caused by antibodies directed against one's own platelets and may affect the mother as well as the fetus. No cases with documented intrauterine fetal bleeding have been reported. The most critical time for the fetus is usually a few days after birth. Hitherto the patient's history has been the best predictor of maternal and neonatal complications. Diagnostic cordocentesis entails a considerable risk and is to be discouraged in most situations. Intrauterine transfusions are effective only for a very limited period. There is no evidence that caesarean section protects the thrombocytopenic infant from intracranial haemorrhage. We therefore recommend restricting caesarean section to obstetric indications and to situations with proven fetal thrombocytopenia and enhanced obstetric risk. The safe cut-off level has yet to be ascertained. It is mandatory to control the newborn's platelet count during the first three days of life.</p></div>","PeriodicalId":77029,"journal":{"name":"Bailliere's clinical haematology","volume":"11 2","pages":"Pages 373-380"},"PeriodicalIF":0.0000,"publicationDate":"1998-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-3536(98)80055-3","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bailliere's clinical haematology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0950353698800553","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

Abstract

Of all pregnant women 1.2% have platelet counts below 100×109/l. Only a small proportion of these have immune thrombocytopenic purpura (ITP). ITP is caused by antibodies directed against one's own platelets and may affect the mother as well as the fetus. No cases with documented intrauterine fetal bleeding have been reported. The most critical time for the fetus is usually a few days after birth. Hitherto the patient's history has been the best predictor of maternal and neonatal complications. Diagnostic cordocentesis entails a considerable risk and is to be discouraged in most situations. Intrauterine transfusions are effective only for a very limited period. There is no evidence that caesarean section protects the thrombocytopenic infant from intracranial haemorrhage. We therefore recommend restricting caesarean section to obstetric indications and to situations with proven fetal thrombocytopenia and enhanced obstetric risk. The safe cut-off level has yet to be ascertained. It is mandatory to control the newborn's platelet count during the first three days of life.

妊娠期免疫性血小板减少性紫癜
在所有孕妇中,1.2%的人血小板计数低于100×109/l。其中只有一小部分患有免疫性血小板减少性紫癜(ITP)。ITP是由针对自身血小板的抗体引起的,可能影响母亲和胎儿。没有病例记录的子宫内胎儿出血的报告。胎儿最关键的时期通常是出生后的几天。迄今为止,患者的病史一直是产妇和新生儿并发症的最佳预测指标。诊断性脐带穿刺具有相当大的风险,在大多数情况下不建议使用。宫内输血仅在非常有限的时间内有效。没有证据表明剖腹产可以保护血小板减少的婴儿免于颅内出血。因此,我们建议将剖腹产限制在产科指征和已证实的胎儿血小板减少症和产科风险增加的情况下。安全临界值还有待确定。在出生后的前三天,必须控制新生儿的血小板计数。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信